Over 235 companies worldwide claim to offer contract manufacturing services for various types of biopharmaceutical frug by roots analysis

Owing to the ever-increasing number of start-ups that are involved in R&D of novel biologics, there is an enormous opportunity for the CMOs in this domain. It is worth emphasizing that, since 2000, more than 115 new CMOs have been established in order to serve to the growing demand for novel biologics that have specific manufacturing requirements. The contemporary contract services market features a mix of large and small-sized CMOs and is characterized by multiple mergers and acquisitions as stakeholders strive to broaden their respective service portfolios. This has enabled several CMOs to offer end-to-end services, ranging from drug development, including preliminary R&D, preclinical and clinical trials, to commercial scale production and regulatory filings

 

• A detailed review of the overall landscape of the biopharmaceutical contract manufacturing market, featuring a comprehensive list of active CMOs and detailed analysis of the manufacturing service providers based on a number of parameters, such as scale of operation (preclinical, clinical and commercial), type of biologics manufactured (peptides / proteins, antibodies, vaccines, cell therapies, gene therapies, antibody drug conjugates, vectors, biosimilars, nucleic acids and others), type of expression systems used (mammalian, microbial and others), year of establishment, employee size, geographical location of the CMO, number of manufacturing facilities, as well as the location of these facilities, GMP compliance, affiliations to regulatory agencies, type of bioreactors used (single-use bioreactors and stainless steel bioreactors), mode of operation of bioreactors (batch, fed-batch and perfusion) and bioprocessing capacity.
• Elaborate profiles of key players that have a diverse range of capabilities for the development, manufacturing and packaging of biologics. Each profile provides an overview of the company, its financial performance (if available), information related to its service portfolio, manufacturing facilities, and details on partnerships, recent developments (expansions), as well as a comprehensive future outlook.
• A detailed discussion on the key enablers in this domain, including certain niche product classes, such as antibody drug conjugates (ADCs), bispecific antibodies, cell therapies, gene therapies and viral vectors, which are likely to have a significant impact on the growth of the contract services market.

A case study on the growing global biosimilars market, highlighting the opportunities for biopharmaceutical CMOs and CDMOs

To order this 750+ page report, which features 200+ figures and 250+ tables, please visit this https://www.rootsanalysis.com/reports/250/request-sample.html

 

The USD 13.9 billion (by 2030) financial opportunity within the biopharmaceutical manufacturing market has been analyzed across the following segments:

• Commonly Outsourced Business Operations
• Active Pharmaceutical Ingredients (API)
• Finished Dosage Formulations (FDF)
• Types of Expression System
• Mammalian
• Microbial
• Others
• Company Size
• Small
• Mid-Sized
• Large and Very Large
• Scale of Operation
• Preclinical
• Clinical
• Commercial
• Key Geographical Region
• North America
• Europe
• Asia-Pacific
• Rest of the World

 

The Biopharma Contract Manufacturing Market (3rd Edition), 2019-2030. report features the following companies, which we identified to be key players in this domain:

• 3P Biopharmaceuticals
• Abzena
• Albany Molecular Research
• BioVectra
• BioXcellence (Boehringer Ingelheim)
• Celonic
• Charles River Laboratories
• ChemPartner
• Cobra Biologics
• CordenPharma
• Cytovance Biologics
• GE Healthcare
• Goodwin Biotechnology
• Grand River Aseptic Manufacturing
• IDT Biologika
• KBI BioPharma
• Kemwell Biopharma
• LFB Biomanufacturing
• Meridian Life Science
• Patheon
• Pfizer CentreOne
• PX'Therapeutics
• Samsung BioLogics
• Sanofi, CEPiA
• Thermo Fisher Scientific
• Vetter Pharma International

 

 

Table of Contents

 

1. Preface

2. Executive Summary

3. Introduction
 

4. Competitive Landscape
 

5. Biopharmaceutical Contract Manufacturing in North America
 

6. Biopharmaceutical Contract Manufacturing in Europe
 

7. Biopharmaceutical Contract Manufacturing in Asia Pacific And the Rest of The World
 

8. Biopharmaceutical Contract Manufacturing in Asia Pacific And the Rest of The World

 

9. Case Study: Outsourcing of Biosimilars
 

10. Case Study: Comparison of Small Molecule and   Large Molecule Drugs / Therapies

 

11. Case Study on In-House Manufacturing
 

12. Collaborations
 

13. Recent Developments
 

14. Capacity Analysis

 

15. Demand Analysis

 

16. Market Forecast

 

17. SWOT Analysis

 

18.  Future of The Biopharmaceutical CMO Market

 

19.  Survey Analysis

 

20. Interview Transcripts

 

21. Appendix 1: List of Non-Industry Players

 

22. Appendix 1: List of Non-Industry Players

 

23. Appendix 3: List of Companies and Organizations

 

To purchase a copy, please visit https://rootsanalysis.com/reports/view_document/biopharma-contract-manufacturing-market-3rd-edition-2019-2030/250.html

 

Contact Details

 

Gaurav Chaudhary

+1 (415) 800 3415

[email protected]